EA201170230A1 - Препарат с модифицированной кинетикой высвобождения и способы его использования - Google Patents

Препарат с модифицированной кинетикой высвобождения и способы его использования

Info

Publication number
EA201170230A1
EA201170230A1 EA201170230A EA201170230A EA201170230A1 EA 201170230 A1 EA201170230 A1 EA 201170230A1 EA 201170230 A EA201170230 A EA 201170230A EA 201170230 A EA201170230 A EA 201170230A EA 201170230 A1 EA201170230 A1 EA 201170230A1
Authority
EA
Eurasian Patent Office
Prior art keywords
retigabin
drug
ethyl
fluorobenzylamino
solvate
Prior art date
Application number
EA201170230A
Other languages
English (en)
Russian (ru)
Inventor
Билджана Наджсомбати
Original Assignee
Вэлиант Фармасьютикалс Интернешнл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201170230(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вэлиант Фармасьютикалс Интернешнл filed Critical Вэлиант Фармасьютикалс Интернешнл
Publication of EA201170230A1 publication Critical patent/EA201170230A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201170230A 2008-07-18 2009-07-17 Препарат с модифицированной кинетикой высвобождения и способы его использования EA201170230A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8216208P 2008-07-18 2008-07-18
PCT/US2009/051052 WO2010009433A1 (en) 2008-07-18 2009-07-17 Modified release formulation and methods of use

Publications (1)

Publication Number Publication Date
EA201170230A1 true EA201170230A1 (ru) 2011-08-30

Family

ID=41550741

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170230A EA201170230A1 (ru) 2008-07-18 2009-07-17 Препарат с модифицированной кинетикой высвобождения и способы его использования

Country Status (16)

Country Link
US (1) US20100120906A1 (https=)
EP (1) EP2318001A4 (https=)
JP (1) JP2011528666A (https=)
KR (1) KR20110052641A (https=)
CN (1) CN102170879B (https=)
AU (1) AU2009270768A1 (https=)
BR (1) BRPI0916000A2 (https=)
CA (1) CA2731008A1 (https=)
CL (1) CL2011000109A1 (https=)
CO (1) CO6351716A2 (https=)
EA (1) EA201170230A1 (https=)
IL (1) IL210683A0 (https=)
MX (1) MX2011000636A (https=)
NZ (1) NZ590885A (https=)
WO (1) WO2010009433A1 (https=)
ZA (1) ZA201102518B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009013613A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013612A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
US10786464B2 (en) * 2009-11-03 2020-09-29 Lupin Limited Modified release formulation of lacosamide
EP2525660A4 (en) * 2010-01-20 2013-08-07 Valeant Pharmaceuticals Int FORMULATION WITH MODIFIED RELEASE AND USE METHOD
EP2525788A2 (en) 2010-01-20 2012-11-28 Glaxo Group Limited Novel retigabine composition
SG191309A1 (en) 2011-01-18 2013-07-31 Glaxo Group Ltd Process for the preparation of retigabine
CN113061089A (zh) 2015-09-23 2021-07-02 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
MA43532A (fr) 2015-12-30 2018-11-07 Adamas Pharmaceuticals Inc Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
CA3162907A1 (en) * 2019-12-02 2021-06-10 Xenon Pharmaceuticals Inc. Pediatric immediate-release formulation of the potassium channel opener ezogabine
CN117321031A (zh) * 2021-03-19 2023-12-29 艾可斯外扎根股份有限公司 Kv7通道开放剂的前药

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) * 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
JP2000086509A (ja) * 1998-09-14 2000-03-28 Taisho Yakuhin Kogyo Kk ソファルコン含有製剤の製造方法
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
NZ527771A (en) * 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
WO2001066081A2 (de) * 2000-03-08 2001-09-13 Awd.Pharma Gmbh & Co.Kg Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
WO2002043704A1 (fr) * 2000-12-01 2002-06-06 Kyowa Hakko Kogyo Co., Ltd. Composition a solubilite ou absorbabilite orale amelioree
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
KR100425226B1 (ko) * 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
GB0120835D0 (en) * 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
AU2003260336C1 (en) * 2002-07-29 2008-05-29 Glaxo Group Limited Sustained release formulations comprising lamotrigine
DE60324609D1 (de) * 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
JP2004131393A (ja) * 2002-10-08 2004-04-30 Kowa Co 易溶出性製剤
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
JP2007506775A (ja) * 2003-09-26 2007-03-22 アルザ・コーポレーシヨン 漸増する放出速度を表す制御放出製剤
GB0324574D0 (en) * 2003-10-21 2003-11-26 Glaxo Group Ltd Novel compositions
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
US20080020041A1 (en) * 2004-10-19 2008-01-24 Ayres James W Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US20100285123A1 (en) * 2005-06-20 2010-11-11 Rudresha Korlakunte Virupakshalah Prasad Controlled Release Dosage Formulation of Duloxetine
EP2404604B1 (en) * 2006-01-05 2019-02-06 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US8558470B2 (en) * 2006-01-20 2013-10-15 Point Somee Limited Liability Company Adaptive current regulation for solid state lighting
USD601689S1 (en) * 2006-05-12 2009-10-06 Glaxo Group Limited Pharmaceutical tablet
CA2670966A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators

Also Published As

Publication number Publication date
EP2318001A4 (en) 2013-02-20
CN102170879B (zh) 2014-03-05
KR20110052641A (ko) 2011-05-18
BRPI0916000A2 (pt) 2019-09-24
EP2318001A1 (en) 2011-05-11
IL210683A0 (en) 2011-03-31
AU2009270768A1 (en) 2010-01-21
US20100120906A1 (en) 2010-05-13
CL2011000109A1 (es) 2011-11-25
ZA201102518B (en) 2012-06-27
JP2011528666A (ja) 2011-11-24
MX2011000636A (es) 2011-08-03
WO2010009433A1 (en) 2010-01-21
CA2731008A1 (en) 2010-01-21
CN102170879A (zh) 2011-08-31
NZ590885A (en) 2013-01-25
CO6351716A2 (es) 2011-12-20

Similar Documents

Publication Publication Date Title
EA201170230A1 (ru) Препарат с модифицированной кинетикой высвобождения и способы его использования
CA2787907A1 (en) Modified release formulation and methods of use
ES2801725T3 (es) Formulaciones farmacéuticas que incluyen un compuesto de amina
CA2747396C (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
JP2012514624A5 (https=)
US8563036B2 (en) Pharmaceutical compositions comprising Brivaracetam
US10729653B2 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
AU2015218642A1 (en) Compositions of pentosan polysulfate salts for oral administration and methods of use
EA200701575A1 (ru) Формуляция леветирацетама длительного высвобождения
EA200900270A1 (ru) Системы регулируемого высвобождения и способ их приготовления
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
CA2611114A1 (en) An entacapone-containing oral dosage form
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
JP2013533303A (ja) 保存に安定な製剤を製造するための結合剤の使用
JP2011528666A5 (https=)
CA3077514A1 (en) Delayed release deferiprone tablets and methods of using the same
JP2019218379A (ja) 肝障害の治療方法
JP2017206535A (ja) 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法
CA3251549A1 (en) ORAL DOSAGE FORMS OF THE TR.BETA. AGONIST, VK2809, FOR THE TREATMENT OF LIVER DISORDERS, AND METHODS FOR PREPARING THESE
JP2018510916A (ja) 医薬処方物
CN107661326A (zh) 用于遗尿的药物制剂及其使用方法
CN102215828A (zh) 包含2-氧代-1-吡咯烷衍生物的延长释放制剂
JP2018536707A5 (https=)
CA2543497A1 (en) Controlled release analgesic suspensions
RU2011110756A (ru) Фармацевтическая композиция в виде разовой пероральной дозы, содержащая леводопу, карбидопу и энтакапон, или их соли